

## Datasheet: MCA2568A647 BATCH NUMBER 150869

Description:	MOUSE ANTI CAT CD134:Alexa Fluor® 647
Specificity:	CD134
Other names:	OX40
Format:	ALEXA FLUOR® 647
Product Type:	Monoclonal Antibody
Clone:	7D6
lsotype:	lgG1
Quantity:	100 TESTS/1ml

## **Product Details**

Applications	derived from testing w communications from	the following application , peer-reviewed publica se refer to references in endations, please visit <u>w</u>	tions or personal dicated for further			
		Yes No	Not Determined	Suggested Dilution		
	Flow Cytometry	•		Neat - 1/5		
	Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are give a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.					
Target Species	Cat					
Species Cross Reactivity	Does not react with:Mouse Reacts weakly with:Human <b>N.B.</b> Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.					
Product Form	Purified IgG conjugated to Alexa Fluor® 647 - liquid					
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)			
	Alexa Fluor®647	650	665			
Preparation	Purified IgG prepared supernatant	by affinity chromato	graphy on Protein G fror	n tissue culture		

Buffer Solution	Phosphate buffered saline
Preservative	0.09% Sodium Azide (NaN <sub>3</sub> )
Stabilisers	
	1% Bovine Serum Albumin
Approx. Protein	IgG concentration 0.05mg/ml
Concentrations	ige concentration closing/init
Immunogen	CHO-derived feline CD134-Fc fusion protein.
RRID	AB_2207244
Fusion Partners	Spleen cells from immunised Balb/c mice were fused with cells of the NS0 mouse myeloma cell line.
Specificity	<b>Mouse anti Cat CD134 antibody, clone 7D6</b> recognizes feline CD134, otherwise known as OX40, a 43 kDa type I membrane protein and member of the tumor necrosis factor receptor superfamily, expressed predominantly by CD4+ activated T cells, and a key regulator of T cell-dependent immune responses.
	CD134 has been identified as the receptor for the OX40 ligand, CD252, expressed by activated B cells, acting as a co-stimulatory signal for the stimulation and secretion of immunoglobulins. CD134 has also been identified as a binding receptor for Feline Immunodeficiency Virus (FIV), acting along with CXC chemokine receptor 4 (CXCR4) to facilitate the entry of the virus into CD4+ primary target cells.
Flow Cytometry	Use 10ul of the suggested working dilution to label 1x10 <sup>6</sup> cells in 100ul.
Flow Cytometry References	<ol> <li>Willett, B.J. <i>et al.</i> (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J <u>Virol. 81: 9665-79.</u></li> <li>Willett, B.J. <i>et al.</i> (2009) Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. <u>Mol</u></li> </ol>
	<ol> <li>Willett, B.J. <i>et al.</i> (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J <u>Virol. 81: 9665-79.</u></li> <li>Willett, B.J. <i>et al.</i> (2009) Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. <u>Mol Immunol. 46: 1020-30.</u></li> </ol>
	<ol> <li>Willett, B.J. <i>et al.</i> (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J <u>Virol. 81: 9665-79.</u></li> <li>Willett, B.J. <i>et al.</i> (2009) Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. <u>Mol Immunol. 46: 1020-30.</u></li> <li>McDonnel, S.J. <i>et al.</i> (2012) Pharmacologic reactivation of latent feline</li> </ol>
	<ol> <li>Willett, B.J. <i>et al.</i> (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J <u>Virol. 81: 9665-79.</u></li> <li>Willett, B.J. <i>et al.</i> (2009) Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. <u>Mol Immunol. 46: 1020-30.</u></li> </ol>
	<ol> <li>Willett, B.J. <i>et al.</i> (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J <u>Virol. 81: 9665-79.</u></li> <li>Willett, B.J. <i>et al.</i> (2009) Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. Mol <u>Immunol. 46: 1020-30.</u></li> <li>McDonnel, S.J. <i>et al.</i> (2012) Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. <u>Virus Res. 170 (1-2): 174-9.</u></li> <li>Stüber, E. &amp; Strober, W. (1996) The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med. 183 (3): 979-89.</li> </ol>
References	<ol> <li>Willett, B.J. <i>et al.</i> (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J <u>Virol. 81: 9665-79.</u></li> <li>Willett, B.J. <i>et al.</i> (2009) Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. Mol <u>Immunol. 46: 1020-30.</u></li> <li>McDonnel, S.J. <i>et al.</i> (2012) Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. <u>Virus Res. 170 (1-2): 174-9.</u></li> <li>Stüber, E. &amp; Strober, W. (1996) The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med. 183 (3):</li> </ol>
References	<ol> <li>Willett, B.J. <i>et al.</i> (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J <u>Virol. 81: 9665-79.</u></li> <li>Willett, B.J. <i>et al.</i> (2009) Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. Mol <u>Immunol. 46: 1020-30.</u></li> <li>McDonnel, S.J. <i>et al.</i> (2012) Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. <u>Virus Res. 170 (1-2):</u> <u>174-9.</u></li> <li>Stüber, E. &amp; Strober, W. (1996) The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. <u>J Exp Med. 183 (3):</u> <u>979-89.</u></li> <li>de Parseval, A. <i>et al.</i> (2004) Feline immunodeficiency virus targets activated CD4+ T</li> </ol>
References Further Reading	<ol> <li>Willett, B.J. <i>et al.</i> (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J <u>Virol. 81: 9665-79.</u></li> <li>Willett, B.J. <i>et al.</i> (2009) Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. Mol <u>Immunol. 46: 1020-30.</u></li> <li>McDonnel, S.J. <i>et al.</i> (2012) Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. <u>Virus Res. 170 (1-2): 174-9.</u></li> <li>Stüber, E. &amp; Strober, W. (1996) The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med. 183 (3): <u>979-89.</u></li> <li>de Parseval, A. <i>et al.</i> (2004) Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. <u>Proc Natl Acad Sci U S A. 101 (35): 13044-9.</u></li> </ol>

	protected from light. Avoid repeated freezing and thawing as the antibody. Should this product contain a precipitate we recommobefore use.	•
Guarantee	12 months from date of despatch	
Acknowledgements	This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsba CA 92008 USA or outlicensing@thermofisher.com	
Health And Safety Information	Material Safety Datasheet documentation #10041 available at: https://www.bio-rad-antibodies.com/SDS/MCA2568A647 10041	
Regulatory	For research purposes only	
Related Produc	cts	
Recommended No	egative Controls	
	VE CONTROL:Alexa Fluor® 647 (MCA928A647) VE CONTROL:Alexa Fluor® 647 (MCA1209A647)	

North & South	Tel: +1 800 265 7376	Norldwide	Tel: +44 (0)1865 852 700	Europe	Tel: +49 (0) 89 8090 95 21
America	Fax: +1 919 878 3751		Fax: +44 (0)1865 852 739		Fax: +49 (0) 89 8090 95 50
	Email: antibody_sales_us@bio-rad.c	com	Email: antibody_sales_uk@bio-rad	d.com	Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M367182:200529'

## Printed on 18 Jan 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint